This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bharaj, B. Articles by Diamandis, E. P. Search for Related Content PubMed PubMed Citation Articles by Bharaj, B. Articles by Diamandis, E. P.

TA Repeat Polymorphism of the 5-Reductase Gene and Breast Cancer

Department of Pathology and Laboratory Medicine, Mount Sinai Hospital [B. B., A. S., E. P. D.] and Department of Laboratory Medicine and Pathobiology, University of Toronto [B. B., A. S., E. P. D.], Toronto, Ontario M5G 1X5, Canada, and Department of Gynecologic Oncology, Institute of Obstetrics and Gynecology, University of Turin, Turin 10128, Italy [M. G.]

There is increasing evidence that androgens play a significant role in the development and progression of breast cancer. 5-Reductase (SRD5A2) is an enzyme that is expressed in androgen-dependent tissues, and it catalyzes the reduction of testosterone to its more bioactive form, dihydrotestosterone, which then transactivates a number of genes. One of these genes encodes for prostate-specific antigen (PSA), a favorable prognostic factor in breast cancer. The 3' untranslated region of the SRD5A2 gene contains either no TA repeats [(TA)₀] or 9 [(TA)₉] or 18 [(TA)₁₈] repeats. Variations in the length of these dinucleotide repeats have been reported to influence the enzymatic activity of SRD5A2.

In this study, we determined the TA genotypes in DNA from 141 well-characterized breast tumors and in DNA from whole blood of 70 women without cancer. The presence of TA genotypes was then associated with tumor cytosolic PSA concentrations and with clinicopathological variables, including disease-free survival and overall survival. Three genotypes, (TA)₀ homozygote, (TA)₀/(TA)₉ heterozygote, and (TA)₉ homozygote, were identified. No (TA)₁₈ alleles were detected in any of the two patient groups. A statistically significant association between high PSA concentrations and (TA)₀/(TA)₉ or (TA)₉ genotypes was observed (P = 0.004). (TA)₀/(TA)₉ or (TA)₉ genotypes were found less frequently in patients at stage III or IV disease. TA genotypes were not associated with other clinicopathological variables by contingency table analysis. Patients with (TA)₀/(TA)₉ or (TA)₉ repeats, when compared to those with genotypes homozygous for the (TA)₀ allele, showed a significant reduction in the risk for relapse (P = 0.043). Long-term studies are needed to investigate the relevance of this polymorphism to breast cancer susceptibility.

This article has been cited by other articles:

				V. K. Sharma, N. Kumar, S. K. Brahmachari, and S. Ramachandran Abundance of dinucleotide repeats and gene expression are inversely correlated: a role for gene function in addition to intron length Physiol Genomics, September 11, 2007; 31(1): 96 - 103. [Abstract] [Full Text] [PDF]

				C. H. van Gils, N. C. Onland-Moret, M. Roest, P. A. H. van Noord, and P. H. M. Peeters The V89L Polymorphism in the 5-{alpha}-Reductase Type 2 Gene and Risk of Breast Cancer Cancer Epidemiol. Biomarkers Prev., November 1, 2003; 12(11): 1194 - 1199. [Abstract] [Full Text]

				B. L. Powell, D. Piersma, M. E. Kevenaar, I. L. van Staveren, A. P. N. Themmen, B. J. Iacopetta, and E. M. J. J. Berns Luteinizing Hormone Signaling and Breast Cancer: Polymorphisms and Age of Onset J. Clin. Endocrinol. Metab., April 1, 2003; 88(4): 1653 - 1657. [Abstract] [Full Text] [PDF]

				E. L. Goode, A. M. Dunning, B. Kuschel, C. S. Healey, N. E. Day, B. A. J. Ponder, D. F. Easton, and P. P. D. Pharoah Effect of Germ-Line Genetic Variation on Breast Cancer Survival in a Population-based Study Cancer Res., June 1, 2002; 62(11): 3052 - 3057. [Abstract] [Full Text] [PDF]

				A. B. Spurdle, J. L. Hopper, X. Chen, G. S. Dite, M. R. E. McCredie, G. G. Giles, D. J. Venter, M. C. Southey, D. M. Purdie, and G. Chenevix-Trench The Steroid 5{alpha}-Reductase Type II TA Repeat Polymorphism Is Not Associated with Risk of Breast or Ovarian Cancer in Australian Women Cancer Epidemiol. Biomarkers Prev., December 1, 2001; 10(12): 1287 - 1293. [Abstract] [Full Text] [PDF]